Viatris Inc (VTRS) - Total Assets
Based on the latest financial reports, Viatris Inc (VTRS) holds total assets worth $37.92 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Viatris Inc net assets for net asset value and shareholders' equity analysis.
Viatris Inc - Total Assets Trend (1985–2024)
This chart illustrates how Viatris Inc's total assets have evolved over time, based on quarterly financial data.
Viatris Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Viatris Inc's total assets of $37.92 Billion consist of 22.9% current assets and 77.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.8% |
| Accounts Receivable | $3.52 Billion | 8.5% |
| Inventory | $3.85 Billion | 9.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $17.07 Billion | 41.1% |
| Goodwill | $9.13 Billion | 22.0% |
Asset Composition Trend (1985–2024)
This chart illustrates how Viatris Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Viatris Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Viatris Inc's current assets represent 22.9% of total assets in 2024, a decrease from 79.5% in 1985.
- Cash Position: Cash and equivalents constituted 1.8% of total assets in 2024, down from 26.8% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 63.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is intangible assets at 41.1% of total assets.
Viatris Inc Competitors by Total Assets
Key competitors of Viatris Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Viatris Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.51 | 1.22 |
| Quick Ratio | 0.79 | 0.96 | 0.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.59 Billion | $3.80 Billion | $2.30 Billion |
Viatris Inc - Advanced Valuation Insights
This section examines the relationship between Viatris Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.19 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | -13.0% |
| Total Assets | $41.50 Billion |
| Market Capitalization | $17.32 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Viatris Inc's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Viatris Inc's assets decreased by 13.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Viatris Inc (1985–2024)
The table below shows the annual total assets of Viatris Inc from 1985 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $41.50 Billion | -12.97% |
| 2023-12-31 | $47.69 Billion | -4.67% |
| 2022-12-31 | $50.02 Billion | -8.79% |
| 2021-12-31 | $54.84 Billion | -10.90% |
| 2020-12-31 | $61.55 Billion | +96.93% |
| 2019-12-31 | $31.26 Billion | -4.52% |
| 2018-12-31 | $32.73 Billion | -8.58% |
| 2017-12-31 | $35.81 Billion | +3.11% |
| 2016-12-31 | $34.73 Billion | +55.95% |
| 2015-12-31 | $22.27 Billion | +40.75% |
| 2014-12-31 | $15.82 Billion | +3.44% |
| 2013-12-31 | $15.29 Billion | +28.18% |
| 2012-12-31 | $11.93 Billion | +2.88% |
| 2011-12-31 | $11.60 Billion | +0.53% |
| 2010-12-31 | $11.54 Billion | +6.81% |
| 2009-12-31 | $10.80 Billion | +3.93% |
| 2008-12-31 | $10.39 Billion | -8.45% |
| 2007-12-31 | $11.35 Billion | +166.89% |
| 2006-12-31 | $4.25 Billion | +127.42% |
| 2005-12-31 | $1.87 Billion | -12.42% |
| 2004-12-31 | $2.14 Billion | +13.29% |
| 2003-12-31 | $1.89 Billion | +8.01% |
| 2002-12-31 | $1.75 Billion | +7.95% |
| 2001-12-31 | $1.62 Billion | +10.28% |
| 2000-12-31 | $1.47 Billion | +9.30% |
| 1999-12-31 | $1.34 Billion | +11.15% |
| 1998-12-31 | $1.21 Billion | +42.33% |
| 1997-12-31 | $847.80 Million | +9.03% |
| 1996-12-31 | $777.60 Million | +12.37% |
| 1995-12-31 | $692.00 Million | +26.69% |
| 1994-12-31 | $546.20 Million | +35.43% |
| 1993-12-31 | $403.30 Million | +14.87% |
| 1992-12-31 | $351.10 Million | +54.87% |
| 1991-12-31 | $226.70 Million | +33.67% |
| 1990-12-31 | $169.60 Million | +23.35% |
| 1989-12-31 | $137.50 Million | +22.01% |
| 1988-12-31 | $112.70 Million | +3.58% |
| 1987-12-31 | $108.80 Million | +35.49% |
| 1986-12-31 | $80.30 Million | +43.39% |
| 1985-12-31 | $56.00 Million | -- |
About Viatris Inc
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and … Read more